Walking back osteosarcoma steps: proteomic profiling of bone marrow mesenchymal stem cells and primary and lung colonizing osteosarcoma human cell lines.

Autores
Valenzuela Alvarez, Matias Juan Pablo; Matos, Bruno; Correa, Alejandro; Makiya, Mónica; Bolontrade, Marcela Fabiana
Año de publicación
2021
Idioma
español castellano
Tipo de recurso
documento de conferencia
Estado
versión publicada
Descripción
Osteosarcoma (OS), the most common malignant bone tumor, has a 20% five-year survival rate for metastatic disease and treatment-resistant patients. Rapid lung dissemination and acquired chemotherapy resistance remain as major clinical challenges. Mesenchymal stem cells (MSC) may contribute directly or indirectly to OS origin and progression. To identify potential metastasis biomarkers, we made a proteomic screening of non-metastatic SAOS2, metastatic LM7 OS cells and BM-MSC using a shotgun approach by a tandem nanocapillary liquid chromatography-mass spectrometry system. We identified 1049 proteins for BM-MSC, 1567 for SAOS2, and 1424 for LM7. To obtain gene ontology terms of the identified proteins, an enrichment analysis of the gene groups was carried out. The three cell populations shared 661 proteins corresponding to protein metabolism, metabolism, and energy-related pathways (25.72%, 22.37%, and 22.37% respectively). Individually, SAOS2 and LM7 cells showed the same number of shared proteins with BM-MSC, but the 64-shared proteins were not the same. Most relevant differences were that VEGF and PDGF signaling pathways were 2.25 fold-increased in LM7-MSC vs. SAOS2-MSC shared proteins. Further, citric acid and electron transport pathways were upregulated in SAOS2-MSC shared proteins. A comparison between SAOS2 and LM7 also shows upregulation of VEGF/PDGF signaling and other metastatic-related pathways in LM7 cells. Our results on the comparison of both OS cells to MSC, suggest that MSC may have a relevant role in OS progression, dictating not only tumor initiation but also metastatic dissemination. Further, LM7 cells had higher expression levels of proteins related to a mesenchymal phenotype and stem-related genes, suggesting a closer relation with MSC. Lung disease remains a major mortality factor in OS. Identification of mechanisms and differentially expressed genes associated with metastasis would help in discovering promising markers and therapeutic targets.
Fil: Valenzuela Alvarez, Matias Juan Pablo. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina
Fil: Matos, Bruno. Instituto Carlos Chagas Fiocruz ; Brasil
Fil: Correa, Alejandro. Instituto Carlos Chagas Fiocruz ; Brasil
Fil: Makiya, Mónica. Hospital Italiano; Argentina
Fil: Bolontrade, Marcela Fabiana. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina
LXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunión Anual de la Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de Nanomedicinas
Argentina
Sociedad Argentina de investigación clínica
Sociedad Argentina de Inmunología
Asociación Argentina de Farmacología Experimental
Asociación Argentina de Nanomedicinas
Materia
OSTEOSARCOMA
MESENCHYMAL STEM CELLS
METASTASIS
BIOMARKERS
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/198484
Acceder
id CONICETDig_56feed6a3870e61ec7b13ede946638c6
oai_identifier_str oai:ri.conicet.gov.ar:11336/198484
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Walking back osteosarcoma steps: proteomic profiling of bone marrow mesenchymal stem cells and primary and lung colonizing osteosarcoma human cell lines.Valenzuela Alvarez, Matias Juan PabloMatos, BrunoCorrea, AlejandroMakiya, MónicaBolontrade, Marcela FabianaOSTEOSARCOMAMESENCHYMAL STEM CELLSMETASTASISBIOMARKERShttps://purl.org/becyt/ford/3.4https://purl.org/becyt/ford/3Osteosarcoma (OS), the most common malignant bone tumor, has a 20% five-year survival rate for metastatic disease and treatment-resistant patients. Rapid lung dissemination and acquired chemotherapy resistance remain as major clinical challenges. Mesenchymal stem cells (MSC) may contribute directly or indirectly to OS origin and progression. To identify potential metastasis biomarkers, we made a proteomic screening of non-metastatic SAOS2, metastatic LM7 OS cells and BM-MSC using a shotgun approach by a tandem nanocapillary liquid chromatography-mass spectrometry system. We identified 1049 proteins for BM-MSC, 1567 for SAOS2, and 1424 for LM7. To obtain gene ontology terms of the identified proteins, an enrichment analysis of the gene groups was carried out. The three cell populations shared 661 proteins corresponding to protein metabolism, metabolism, and energy-related pathways (25.72%, 22.37%, and 22.37% respectively). Individually, SAOS2 and LM7 cells showed the same number of shared proteins with BM-MSC, but the 64-shared proteins were not the same. Most relevant differences were that VEGF and PDGF signaling pathways were 2.25 fold-increased in LM7-MSC vs. SAOS2-MSC shared proteins. Further, citric acid and electron transport pathways were upregulated in SAOS2-MSC shared proteins. A comparison between SAOS2 and LM7 also shows upregulation of VEGF/PDGF signaling and other metastatic-related pathways in LM7 cells. Our results on the comparison of both OS cells to MSC, suggest that MSC may have a relevant role in OS progression, dictating not only tumor initiation but also metastatic dissemination. Further, LM7 cells had higher expression levels of proteins related to a mesenchymal phenotype and stem-related genes, suggesting a closer relation with MSC. Lung disease remains a major mortality factor in OS. Identification of mechanisms and differentially expressed genes associated with metastasis would help in discovering promising markers and therapeutic targets.Fil: Valenzuela Alvarez, Matias Juan Pablo. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; ArgentinaFil: Matos, Bruno. Instituto Carlos Chagas Fiocruz ; BrasilFil: Correa, Alejandro. Instituto Carlos Chagas Fiocruz ; BrasilFil: Makiya, Mónica. Hospital Italiano; ArgentinaFil: Bolontrade, Marcela Fabiana. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; ArgentinaLXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunión Anual de la Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de NanomedicinasArgentinaSociedad Argentina de investigación clínicaSociedad Argentina de InmunologíaAsociación Argentina de Farmacología ExperimentalAsociación Argentina de NanomedicinasFundación Revista Medicina2021info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectReuniónJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/198484Walking back osteosarcoma steps: proteomic profiling of bone marrow mesenchymal stem cells and primary and lung colonizing osteosarcoma human cell lines.; LXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunión Anual de la Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de Nanomedicinas; Argentina; 2021; 161-1620025-7680CONICET DigitalCONICETspainfo:eu-repo/semantics/altIdentifier/url/https://www.saic.org.ar/reunion-anualInternacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-03T09:56:58Zoai:ri.conicet.gov.ar:11336/198484instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-03 09:56:58.51CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Walking back osteosarcoma steps: proteomic profiling of bone marrow mesenchymal stem cells and primary and lung colonizing osteosarcoma human cell lines.
title Walking back osteosarcoma steps: proteomic profiling of bone marrow mesenchymal stem cells and primary and lung colonizing osteosarcoma human cell lines.
spellingShingle Walking back osteosarcoma steps: proteomic profiling of bone marrow mesenchymal stem cells and primary and lung colonizing osteosarcoma human cell lines.
Valenzuela Alvarez, Matias Juan Pablo
OSTEOSARCOMA
MESENCHYMAL STEM CELLS
METASTASIS
BIOMARKERS
title_short Walking back osteosarcoma steps: proteomic profiling of bone marrow mesenchymal stem cells and primary and lung colonizing osteosarcoma human cell lines.
title_full Walking back osteosarcoma steps: proteomic profiling of bone marrow mesenchymal stem cells and primary and lung colonizing osteosarcoma human cell lines.
title_fullStr Walking back osteosarcoma steps: proteomic profiling of bone marrow mesenchymal stem cells and primary and lung colonizing osteosarcoma human cell lines.
title_full_unstemmed Walking back osteosarcoma steps: proteomic profiling of bone marrow mesenchymal stem cells and primary and lung colonizing osteosarcoma human cell lines.
title_sort Walking back osteosarcoma steps: proteomic profiling of bone marrow mesenchymal stem cells and primary and lung colonizing osteosarcoma human cell lines.
dc.creator.none.fl_str_mv Valenzuela Alvarez, Matias Juan Pablo
Matos, Bruno
Correa, Alejandro
Makiya, Mónica
Bolontrade, Marcela Fabiana
author Valenzuela Alvarez, Matias Juan Pablo
author_facet Valenzuela Alvarez, Matias Juan Pablo
Matos, Bruno
Correa, Alejandro
Makiya, Mónica
Bolontrade, Marcela Fabiana
author_role author
author2 Matos, Bruno
Correa, Alejandro
Makiya, Mónica
Bolontrade, Marcela Fabiana
author2_role author
author
author
author
dc.subject.none.fl_str_mv OSTEOSARCOMA
MESENCHYMAL STEM CELLS
METASTASIS
BIOMARKERS
topic OSTEOSARCOMA
MESENCHYMAL STEM CELLS
METASTASIS
BIOMARKERS
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.4
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Osteosarcoma (OS), the most common malignant bone tumor, has a 20% five-year survival rate for metastatic disease and treatment-resistant patients. Rapid lung dissemination and acquired chemotherapy resistance remain as major clinical challenges. Mesenchymal stem cells (MSC) may contribute directly or indirectly to OS origin and progression. To identify potential metastasis biomarkers, we made a proteomic screening of non-metastatic SAOS2, metastatic LM7 OS cells and BM-MSC using a shotgun approach by a tandem nanocapillary liquid chromatography-mass spectrometry system. We identified 1049 proteins for BM-MSC, 1567 for SAOS2, and 1424 for LM7. To obtain gene ontology terms of the identified proteins, an enrichment analysis of the gene groups was carried out. The three cell populations shared 661 proteins corresponding to protein metabolism, metabolism, and energy-related pathways (25.72%, 22.37%, and 22.37% respectively). Individually, SAOS2 and LM7 cells showed the same number of shared proteins with BM-MSC, but the 64-shared proteins were not the same. Most relevant differences were that VEGF and PDGF signaling pathways were 2.25 fold-increased in LM7-MSC vs. SAOS2-MSC shared proteins. Further, citric acid and electron transport pathways were upregulated in SAOS2-MSC shared proteins. A comparison between SAOS2 and LM7 also shows upregulation of VEGF/PDGF signaling and other metastatic-related pathways in LM7 cells. Our results on the comparison of both OS cells to MSC, suggest that MSC may have a relevant role in OS progression, dictating not only tumor initiation but also metastatic dissemination. Further, LM7 cells had higher expression levels of proteins related to a mesenchymal phenotype and stem-related genes, suggesting a closer relation with MSC. Lung disease remains a major mortality factor in OS. Identification of mechanisms and differentially expressed genes associated with metastasis would help in discovering promising markers and therapeutic targets.
Fil: Valenzuela Alvarez, Matias Juan Pablo. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina
Fil: Matos, Bruno. Instituto Carlos Chagas Fiocruz ; Brasil
Fil: Correa, Alejandro. Instituto Carlos Chagas Fiocruz ; Brasil
Fil: Makiya, Mónica. Hospital Italiano; Argentina
Fil: Bolontrade, Marcela Fabiana. Consejo Nacional de Investigaciones Cientificas y Tecnicas. Oficina de Coordinacion Administrativa Houssay. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Hospital Italiano. Instituto de Medicina Traslacional E Ingenieria Biomedica. - Instituto Universitario Hospital Italiano de Buenos Aires. Instituto de Medicina Traslacional E Ingenieria Biomedica.; Argentina
LXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunión Anual de la Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de Nanomedicinas
Argentina
Sociedad Argentina de investigación clínica
Sociedad Argentina de Inmunología
Asociación Argentina de Farmacología Experimental
Asociación Argentina de Nanomedicinas
description Osteosarcoma (OS), the most common malignant bone tumor, has a 20% five-year survival rate for metastatic disease and treatment-resistant patients. Rapid lung dissemination and acquired chemotherapy resistance remain as major clinical challenges. Mesenchymal stem cells (MSC) may contribute directly or indirectly to OS origin and progression. To identify potential metastasis biomarkers, we made a proteomic screening of non-metastatic SAOS2, metastatic LM7 OS cells and BM-MSC using a shotgun approach by a tandem nanocapillary liquid chromatography-mass spectrometry system. We identified 1049 proteins for BM-MSC, 1567 for SAOS2, and 1424 for LM7. To obtain gene ontology terms of the identified proteins, an enrichment analysis of the gene groups was carried out. The three cell populations shared 661 proteins corresponding to protein metabolism, metabolism, and energy-related pathways (25.72%, 22.37%, and 22.37% respectively). Individually, SAOS2 and LM7 cells showed the same number of shared proteins with BM-MSC, but the 64-shared proteins were not the same. Most relevant differences were that VEGF and PDGF signaling pathways were 2.25 fold-increased in LM7-MSC vs. SAOS2-MSC shared proteins. Further, citric acid and electron transport pathways were upregulated in SAOS2-MSC shared proteins. A comparison between SAOS2 and LM7 also shows upregulation of VEGF/PDGF signaling and other metastatic-related pathways in LM7 cells. Our results on the comparison of both OS cells to MSC, suggest that MSC may have a relevant role in OS progression, dictating not only tumor initiation but also metastatic dissemination. Further, LM7 cells had higher expression levels of proteins related to a mesenchymal phenotype and stem-related genes, suggesting a closer relation with MSC. Lung disease remains a major mortality factor in OS. Identification of mechanisms and differentially expressed genes associated with metastasis would help in discovering promising markers and therapeutic targets.
publishDate 2021
dc.date.none.fl_str_mv 2021
dc.type.none.fl_str_mv info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/conferenceObject
Reunión
Journal
http://purl.org/coar/resource_type/c_5794
info:ar-repo/semantics/documentoDeConferencia
status_str publishedVersion
format conferenceObject
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/198484
Walking back osteosarcoma steps: proteomic profiling of bone marrow mesenchymal stem cells and primary and lung colonizing osteosarcoma human cell lines.; LXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunión Anual de la Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de Nanomedicinas; Argentina; 2021; 161-162
0025-7680
CONICET Digital
CONICET
url http://hdl.handle.net/11336/198484
identifier_str_mv Walking back osteosarcoma steps: proteomic profiling of bone marrow mesenchymal stem cells and primary and lung colonizing osteosarcoma human cell lines.; LXVI Reunión Anual de la Sociedad Argentina de Investigación Clínica; LXIX Reunión Anual de la Sociedad Argentina de Inmunología; LIII Reunión Anual de la Asociación Argentina de Farmacología Experimental y XI Reunión Anual de la Asociación Argentina de Nanomedicinas; Argentina; 2021; 161-162
0025-7680
CONICET Digital
CONICET
dc.language.none.fl_str_mv spa
language spa
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.saic.org.ar/reunion-anual
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
dc.coverage.none.fl_str_mv Internacional
dc.publisher.none.fl_str_mv Fundación Revista Medicina
publisher.none.fl_str_mv Fundación Revista Medicina
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1842269431914299392
score 13.13397

Publicaciones similares